High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022–23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)

  06 April 2024

The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) conducted a study in Cambodia from January 2022 to June 2023, revealing a high prevalence of ceftriaxone-resistant, MDR, and XDR N. gonorrhoeae. The study found that resistance to ceftriaxone, cefixime, azithromycin, and ciprofloxacin was 15.4%, 43.1%, 14.4%, and 97.1%, respectively. 6.2% of isolates were resistant to all four antimicrobials, indicating the need for expanded surveillance, revision of treatment, mandatory test of cure, enhanced sexual contact notification, and the development of novel antimicrobials for gonorrhoea treatment.

 

Author(s): V Ouk et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed